Registry Tracking Treatments and Outcomes in Adults With Myelodysplastic Syndromes in Asia
Collects information on people with myelodysplastic syndromes in Asia and their treatments over time.
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- Singapore, SingaporeSee the siteAlso in 2 other countries, 2 sites
- Trial code
- Registry title
- Asia Myelodysplastic Syndrome (MDS) Registry
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 11 Aug 2026
- Expected to end
- 30 Sept 2027
- Type of study
- Observational
- Treatments tested
- Prescribed treatments for myelodysplastic syndromes (MDS)
- Record updated
- 8 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults in Asia who were diagnosed with myelodysplastic syndromes (MDS) in set time periods.
- Age
- 18 years or older at the first MDS diagnosis.
- Sex
- All sexes can join.
- Disease stage
- MDS diagnosed under WHO 2008, WHO 2016 or WHO 2022 criteria, within 100 days of the diagnostic bone marrow aspirate.
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:
- Aged at least 18 years at initial diagnosis of MDS
- Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
- Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate
- Aged at least 18 years at initial diagnosis of MDS; and
- Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and
- Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate
Who cannot take part
- None
Where in Singapore
Also in 2 other countries, 2 sites
- Singapore General HospitalSingapore, SingaporeContact: Nurul Aidah, Site 0003Taking people
About the trial
What the trial wants to find out
The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.
The group in the trial
- Group 1
Participants diagnosed with myelodysplastic syndromes (MDS)
Treatment: Prescribed treatments for myelodysplastic syndromes (MDS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Asia Myelodysplastic Syndrome (MDS) Registry
- Plain-language title
- Registry Tracking Treatments and Outcomes in Adults With Myelodysplastic Syndromes in AsiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 October 2026